Literature DB >> 16319716

Alpha-synuclein and chaperones in dementia with Lewy bodies.

Ippolita Cantuti-Castelvetri1, Jochen Klucken, Martin Ingelsson, Karunya Ramasamy, Pamela J McLean, Matthew P Frosch, Bradley T Hyman, David G Standaert.   

Abstract

The protein alpha-synuclein (ASYN) is thought to be involved in the development of dementia with Lewy bodies (DLB). Overexpression of ASYN has been linked to cellular toxicity and human disease, and in experimental models, chaperones such as heat shock proteins (HSPs) are protective against ASYN toxicity. We have assessed the abundance of mRNA for ASYN and chaperones and the abundance and solubility of the encoded proteins in temporal cortex from sporadic human DLB. We found a reduction of ASYN mRNA in DLB (44.9% of control). The abundance of the Triton-soluble fraction (bioavailable protein) was not altered, but there was an increase of the Triton-insoluble component (likely representing aggregates). We evaluated 3 chaperones: HSP70, HSP90, and HDJ1. HSP70 mRNA was increased in DLB, whereas the mRNAs for HSP90 and HDJ1 were unchanged. HSP70 accumulated in the Triton-soluble fraction, whereas HSP90 and HDJ1 proteins accumulated in the Triton-insoluble fraction. These observations suggest that sporadic DLB is not associated with overexpression of ASYN. Rather, the persistence of normal soluble ASYN protein levels, despite the reduction of its mRNA, suggests a primary defect in clearance of the protein. However, this reduced clearance cannot be attributed to a failure of chaperone expression, because their mRNA is unchanged or increased in the DLB brain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16319716     DOI: 10.1097/01.jnen.0000190063.90440.69

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  31 in total

Review 1.  Biochemical premotor biomarkers for Parkinson's disease.

Authors:  Brit Mollenhauer; Jing Zhang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

Review 2.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

3.  Molecular interaction of α-synuclein with tubulin influences on the polymerization of microtubule in vitro and structure of microtubule in cells.

Authors:  R M Zhou; Y X Huang; X L Li; C Chen; Q Shi; G R Wang; C Tian; Z Y Wang; Y Y Jing; C Gao; X P Dong
Journal:  Mol Biol Rep       Date:  2009-10-14       Impact factor: 2.316

4.  The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen.

Authors:  Jack T Rogers; Sohan Mikkilineni; Ippolita Cantuti-Castelvetri; Deborah H Smith; Xudong Huang; Sanghamitra Bandyopadhyay; Catherine M Cahill; Maria L Maccecchini; Debomoy K Lahiri; Nigel H Greig
Journal:  J Neural Transm (Vienna)       Date:  2011-01-08       Impact factor: 3.575

5.  Development and screening of contrast agents for in vivo imaging of Parkinson's disease.

Authors:  Krista L Neal; Naomi B Shakerdge; Steven S Hou; William E Klunk; Chester A Mathis; Evgueni E Nesterov; Timothy M Swager; Pamela J McLean; Brian J Bacskai
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

Review 6.  Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Authors:  Heather E Allen Reish; David G Standaert
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

7.  Determining nuclear localization of alpha-synuclein in mouse brains.

Authors:  Z Huang; Z Xu; Y Wu; Y Zhou
Journal:  Neuroscience       Date:  2011-10-19       Impact factor: 3.590

Review 8.  Synaptic protein alterations in Parkinson's disease.

Authors:  Ilse S Pienaar; David Burn; Christopher Morris; David Dexter
Journal:  Mol Neurobiol       Date:  2011-12-29       Impact factor: 5.590

9.  Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy.

Authors:  Jill R Crittenden; Ippolita Cantuti-Castelvetri; Esen Saka; Christine E Keller-McGandy; Ledia F Hernandez; Lauren R Kett; Anne B Young; David G Standaert; Ann M Graybiel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

10.  Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.

Authors:  Lonnie Schneider; Jianhua Zhang
Journal:  Mol Neurodegener       Date:  2010-04-13       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.